Progressing backwards, should I switch from Fin to Dut?? Progress Pictures 9/20/2025
The user is experiencing hair loss and is using 2% ketoconazole shampoo, Minoxidil, and Finasteride. They are considering switching from Finasteride to Dutasteride, but others suggest waiting due to a possible shedding phase.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Anyone see no results for 10+ months OR on 0.5mg fin, but then saw improvement later/on 1mg?
A user experienced no visible improvement in hair loss after 10 months on 0.5mg finasteride and increased the dose to 1mg, noticing a possible shedding phase. They also use topical minoxidil, ketoconazole shampoo, and dermastamping, and are seeking others' experiences with similar treatments.
community 20 years old: 6 months of 1MG Fin + 1 month back on topical Min - Shed phase sucks.
A 20-year-old is experiencing hair thinning after 6 months on finasteride and 1 month on topical minoxidil, noting a difficult shedding phase. Others suggest patience and possibly considering dutasteride if needed, while emphasizing the importance of gradual transitions between treatments.
community Good recovery to diffuse thinning
A 25-year-old male with androgenetic alopecia experienced improved hair condition after using finasteride, oral minoxidil, and dutasteride, but later faced diffuse thinning and texture deterioration after a shedding phase. Others suggest patience, continued treatment, and using ketoconazole shampoo, with some sharing similar experiences of post-shed thinning.
community My Shedding Never Stops on Medication 23M
A 23-year-old male experienced initial success with finasteride, topical minoxidil, and ketoconazole for hair loss, but persistent shedding and scalp issues led him to switch to dutasteride without improvement. Users suggest stress management, addressing potential seborrheic dermatitis, and patience with the treatment process.
community My 1.5-year journey: Transitioning from Finasteride/Topical to Dutasteride + Oral Minoxidil (5mg)
The user transitioned from finasteride and topical minoxidil to dutasteride and oral minoxidil, increasing the oral minoxidil dose to 5mg, which led to shedding but also new hair growth. They found oral treatments more effective and convenient, despite initial shedding, and are seeking advice on long-term results and experiences with similar transitions.
Related Research
6 / 6 results
research Managing patterned hair loss – a hair raising task!
This review summarizes existing knowledge on diffuse and patterned alopecia, emphasizing recent advancements in treatment beyond FDA-approved options, but it reports no new clinical findings.
research Treat androgenetic alopecia with antiandrogens, as well as other pharmacological and non-pharmacological interventions
This review discusses current treatment options for androgenetic alopecia, noting that most lack robust evidence for efficacy and safety, highlighting the need for more comprehensive studies.
research Addressing Androgenetic Alopecia-A Complex Disorder-with a Multilateral Treatment Strategy
This review discusses recent advancements in understanding the pathophysiology of androgenetic alopecia and highlights the potential for multilateral topical therapies to improve treatment efficacy with fewer side effects; it reports no new clinical results.
research Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review
This review discusses the potential of using SULT1A1 expression in the scalp as a biomarker to predict response to minoxidil treatment for androgenetic alopecia, but reports no new clinical results.
research Overactive bladder in men
This chapter discusses the increasing prevalence of overactive bladder in aging men, examining potential causes and treatment options, without reporting new clinical results.
research Female Androgenetic Alopecia: An Update on Diagnosis and Management
This review discusses female androgenetic alopecia, highlighting its diagnostic challenges and management strategies, but it reports no new results.